Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Phase I/II Trial of Oral Vorinostat in Combination With Erlotinib in Non-small-cell Lung Cancer Patients With Mutations at Epidermal Growth Factor Receptor With Disease Progression After Erlotinib Treatment

NCT00503971 is registered in ClinicalTrials.gov with Spanish Lung Cancer Group as lead sponsor.

NCT NCT00503971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00503971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Phase I/II Trial of Oral Vorinostat in Combination With Erlotinib in Non-small-cell Lung Cancer Patients With Mutations at Epidermal Growth Factor Receptor With Disease Progression After Erlotinib Treatment
Lead sponsor
Spanish Lung Cancer Group
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2008
Completion date
December 31, 2011
Enrollment
33 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer